Serum and synovial fluid inhibitors of antibody-mediated lymphocytotoxicity in rheumatoid arthritis and systemic lupus erythematosus
β Scribed by Efrain Diaz-Jouanen; Arthur D. Bankhurst; Ronald P. Messner; Ralph C. Williams JR.
- Publisher
- John Wiley and Sons
- Year
- 1976
- Tongue
- English
- Weight
- 612 KB
- Volume
- 19
- Category
- Article
- ISSN
- 0004-3591
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
Many sera from patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) inhibit lymphocyteβdependent antibody cytotoxicity (LDAC). RA synovial fluids also inhibit LDAC. RA serum inhibition was present in high molecular weight and 5S serum fractions, whereas in SLE it was confined to 7S fractions. A correlation between rheumatoid factor activity and LDAC inhibition was noted, and there was some evidence for inhibition of SLE serum acting on effector cells. Inhibition in RA synovial fluid was found in both high molecular weight and very low molecular weight fractions (<4S).
π SIMILAR VOLUMES
## Abstract A patient population admitted to the hospital for either SLE or RA was surveyed for the subsequent development of neoplasms. The frequency of neoplasm in SLE patients appeared to be exaggerated, whereas the frequency of subsequent neoplasm in rheumatoid patients was unexpectedly low. A
Radioimmunoassays for anti-F(ab')z antibodies, which feature the use of goat anti-human Fc antibody for correcting potentiation of IgM anti-F(ab')z antibody titers by endogenous IgM anti-Fc antibodies (rheumatoid factors), are described. Individuals with classic rheumatoid arthritis had significantl